Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of dioscin to preparation of renal injury protection medicament

A technology of diosgenin and kidney injury, which is applied in the application field of diosgenin in the preparation of kidney injury protection drugs, and can solve the problems of no diosgenin, etc.

Inactive Publication Date: 2015-02-18
DALIAN MEDICAL UNIVERSITY
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, there is no relevant report on the application of diosgenin in the protection of kidney damage and in the preparation of kidney protection drugs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of dioscin to preparation of renal injury protection medicament
  • Application of dioscin to preparation of renal injury protection medicament
  • Application of dioscin to preparation of renal injury protection medicament

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 Study on the preventive effect of diosgenin on acute kidney injury in rats with renal ischemia-reperfusion

[0024] 1. Experimental method

[0025] 1.1 Animal model establishment and grouping

[0026] 50 healthy adult SD male rats at 8-10 weeks were randomly divided into 5 groups: sham operation group (Sham), ischemia-reperfusion group (Model), high-dose administration group (dioscin 60 mg / kg), medium-dose Administration group (diosgenin 40 mg / kg), low dose administration group (diosgenin 20 mg / kg). The administration group underwent surgery 7 days after the administration.

[0027] The experimental animals were fasted for 12 h before the operation, had free access to water, and were anesthetized by intraperitoneal injection of 10% chloral hydrate solution (3.5 mL / kg) before the operation, and fixed on the operating table. Make an incision in the middle of the abdomen along the midline of the abdomen, cut and separate the skin, muscles, and linea alba layer...

Embodiment 2

[0060] Example 2 Study on the therapeutic effect of diosgenin on renal fibrosis in rats caused by unilateral ureteral ligation

[0061] 1. Experimental method

[0062] 1.1 Animal model establishment and grouping

[0063] Male SD rats were randomly divided into 5 groups, 10 in each group: sham operation group (Sham group), unilateral ureteral ligation group (Model group), high-dose administration group (diosgenin 60 mg / kg), middle-dose administration group group (diosgenin 40 mg / kg), low-dose administration group (diosgenin 20 mg / kg).

[0064] The experimental animals were fasted for 12 h before operation and had free access to water, and were anesthetized by intraperitoneal injection of 10% chloral hydrate solution (3.5 mL / kg) before operation. Model group and drug treatment group: the left abdominal incision was made to open the abdominal cavity, the left ureter was bluntly separated, the upper middle 1 / 3 was double ligated with 4-0 suture, and the abdominal cavity was clos...

Embodiment 3

[0087] Example 3 Study on the therapeutic effect of diosgenin on renal tubular epithelial cell hypoxia / reoxygenation injury model

[0088] 1. Experimental method

[0089] 1.1 Recovery, culture, subculture and experimental grouping of NRK-52E cells

[0090] The frozen NRK-52E cells were taken out from the liquid nitrogen tank and thawed in a water bath at 37°C. Aspirate the cell suspension and add DMEM / F12 (10% FBS) culture medium, centrifuge at 1000 r / min for 5 min, discard the supernatant and repeat washing once. Dilute and mix with DMEM / F12 (10% FBS) culture medium, inoculate in 50 ml culture flask, place in 5% CO at 37°C 2The cells were left standing in the incubator for 12 hours, and the medium was changed to remove non-adherent cells. After the cells were over 80% full, they were digested and passaged with 0.25% trypsin. The experiment was randomly divided into 5 groups, namely the blank group, the model group, and the three dosage administration groups. Each group was...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of dioscin to the preparation of a renal injury protection medicament. Dioscin has a renal injury protection effect, and can be used for preparing the renal injury protection medicament. Dioscin has an obvious lowering effect on NO (Nitric Oxide), TNOS (Total Nitric Oxide Synthase), iNOS (Inducible Nitric Oxide Synthase), MDA (Malondialdehyde), BUN (Blood Urea Nitrogen) and SCr (Serum Creatinine) rise caused by renal injury, has an obvious increasing effect on the reduction of SOD (Superoxide Dismutase), GSH (Glutathione), GSH-Px (Glutathione Peroxidase) and CAT (Catalase) relative to a Model group, and is dose-dependent. After the intervention of dioscin, the phenomena of large-area renal tubular epithelial cell swelling, brush border disappearance, degenerative necrosis of a part of epithelial cells, blockage of lumens by necrotic and exfoliative cellular debris and the like, which are caused by renal injury are obviously alleviated. Dioscin can be used for preparing a medicinal preparation as an active ingredient according to clinical medication needs. Dioscin has the advantages of safety (no toxic or side effects), effectivity, economy, practicability and the like.

Description

Technical field [0001] Background technique [0002] Invention content [0003] [0004] [0005] [0006] [0007] [0008] [0009] [0010] [0011] Attachment description [0012] figure 1 [0013] figure 2 [0014] image 3 [0015] Figure 4 [0016] Figure 5 [0017] Figure 6 [0018] Figure 7 [0019] Figure 8 [0020] Figure 9 [0021] Figure 10 Detailed ways [0022] [0023] [0024] [0025] [0026] [0027] [0028] [0029] [0030] [0031] [0032] [0033] [0034] [0035] [0036] [0037] [0038] [0039] [0040] [0041] ? ? Premix ex taq [0042] [0043] p p [0044] [0045] [0046] figure 1 [0047] 2.2 BRDU cell proliferation experiment [0048] See the results of BRDU cell proliferation experiment figure 2 EssenceThe results showed that the number of cell proliferation in the Model group was significantly lower than that of the SHAM group and the administration group, and the number of cell proliferation in different concentrations was...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P13/12
CPCA61K31/7048
Inventor 彭金咏尹连红郑玲俐齐蒙许丽娜齐艳许有威韩旭赵艳艳
Owner DALIAN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com